Strongly


An expression of the live unlimited spirit, stories and voices of the MDA community

Clinical Trial Alert: Capricor Seeks Participants for a Phase 2 DMD Study

Researchers at Capricor Therapeutics are looking for ambulatory and non-ambulatory children and adults with Duchenne muscular dystrophy (DMD) to participate in a Phase 2 study. The goal of the study is to evaluate the safety and efficacy of CAP-1002. Researchers hope that this therapy may slow disease progression in heart and skeletal muscle by modulating . . .

Read More

Scenes from MDA’s #RideForStrength and Harley-Davidson’s 115th Anniversary Parade

On Labor Day weekend, Harley-Davidson and the Muscular Dystrophy Association hit the streets of Milwaukee to celebrate Harley’s 115th anniversary — and the 38-year partnership between the iconic American motorcycle maker and MDA. Thousands of riders and bikes convened for Harley’s celebratory 115th Anniversary Parade on Sept. 2. Within the parade was MDA’s Parade of . . .

Read More

The Changing Landscape of LGMD Research: A Conversation with MDA Scientific Portfolio Director Lianna Orlando

Sept. 30th is Limb-Girdle Muscular Dystrophy Awareness Day, which celebrates individuals living with the more than 30 different subtypes of Limb-girdle muscular dystrophy (LGMD). MDA has a long-standing commitment to LGMD — we’ve invested more than $59 million in LGMD-specific research since 1950, including more than $2.8 million in current active grants. MDA Scientific Portfolio . . .

Read More

UC Davis Researchers Seek DMD Participants for Survey to Improve Clinical Trial Outcome Measurements

In order to develop better methods for capturing the perspective of individuals living with Duchenne muscular dystrophy (DMD) during clinical trials, researchers at the University of California Davis Neuromuscular Research Center are seeking participants for an online survey to monitor movement and daily living abilities. The Duchenne Muscular Dystrophy Life-Time Mobility Scale (DMD-LMS) is a . . .

Read More

FDA Announces the Approval of TIGLUTIK, an Oral Suspension Form of riluzole, for the Treatment of ALS

On September 6th, the U.S. Food and Drug Administration (FDA) announced the approval of TIGLUTIK, an oral suspension form of riluzole for the treatment of amyotrophic lateral sclerosis (ALS). TIGLUTIK, marketed by ITF Pharma, the U.S. subsidiary of Italian specialty pharmaceutical company Italfarmaco, is an oral suspension formulation of riluzole, which has been available in . . .

Read More

Three Major Patient Advocacy Groups Focused on CMT Research to Collaborate on FDA “Voice of the Patient Report” and Patient-Focused Meeting

In honor of Charcot-Marie-Tooth (CMT) Awareness Month, the Muscular Dystrophy Association joins the Charcot-Marie-Tooth Association (CMTA) and the Hereditary Neuropathy Foundation (HNF) to host an externally led patient-focused drug development (PFDD) meeting for CMT. The PFDD meeting is being held on Friday, Sept. 28 at the College Park Marriott Hotel and Conference Center in Hyattsville, . . .

Read More